BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 35095286)

  • 1. Effectiveness and Safety of Anlotinib Monotherapy for Patients with Extensive-stage Small-Cell Lung Cancer Who Progressed to Chemotherapy: A Real-world Exploratory Study.
    Li Y; Sun Z; Sun W; Wang H; Zu J
    Clin Med Insights Oncol; 2022; 16():11795549211067184. PubMed ID: 35095286
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of Anlotinib Monotherapy as Third-Line Therapy for Elderly Patients with Non-Small Cell Lung Cancer: A Real-World Exploratory Study.
    Jiang HT; Li W; Zhang B; Gong Q; Qie HL
    Int J Gen Med; 2021; 14():7625-7637. PubMed ID: 34754233
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of Anlotinib for Elderly Patients with Previously Treated Extensive-Stage SCLC and the Prognostic Significance of Common Adverse Reactions.
    Song PF; Xu N; Li Q
    Cancer Manag Res; 2020; 12():11133-11143. PubMed ID: 33173346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Activity and Safety of Anlotinib Combined with PD-1 Blockades for Patients with Previously Treated Small Cell Lung Cancer.
    Hao YY; Qiao YP; Cheng JD
    Int J Gen Med; 2021; 14():10483-10493. PubMed ID: 35002304
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world efficacy and safety of anlotinib as third- or further-line treatment in refractory small cell lung cancer.
    Gao X; Peng L; Zhang L; Huang K; Yi C; Li B; Meng X; Li J
    J Cancer Res Clin Oncol; 2022 Oct; 148(10):2661-2671. PubMed ID: 34748028
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pretreatment prognostic nutritional index is a prognostic marker for extensive-stage small cell lung cancer patients treated with anlotinib.
    Liu J; Li S; Zhang S; Yang C; Zhang L; Zhang B; Cheng Y; Wang C
    J Thorac Dis; 2020 Oct; 12(10):5765-5773. PubMed ID: 33209408
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of VEGFR2 gene polymorphism on the clinical outcomes of apatinib for patients with chemotherapy-refractory extensive-stage SCLC: a real-world retrospective study.
    Geng N; Ding CM; Liu ZK; Song S; Hu WX
    Int J Clin Oncol; 2021 Apr; 26(4):670-683. PubMed ID: 33392882
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic effectiveness of anlotinib combined with etoposide in extensive-stage small-cell lung cancer: a single-arm, phase II trial.
    Wu Y; Zhou X; Zhao W; Wang Q; Han Z; Wang L; Zhou W; Zhou T; Song H; Chen Y; Yang K; Shi L; Pan B; Guo R; Zhou G; Jiang F; Feng J; Shen B
    Invest New Drugs; 2023 Dec; 41(6):825-833. PubMed ID: 37837490
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Response to first-line treatment predicts progression-free survival benefit of small-cell lung cancer patients treated with anlotinib.
    Qin B; Xin L; Hou Q; Yang B; Zhang J; Qi X; Wei Y; Hu Y; Xiong Q
    Cancer Med; 2021 Jun; 10(12):3896-3904. PubMed ID: 33960145
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of Anlotinib in Patients with Advanced Non-Small Cell Lung Cancer: A Real-World Study.
    Zhong Q; Liu Z
    Cancer Manag Res; 2021; 13():4115-4128. PubMed ID: 34045898
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of Anlotinib for Patients with Advanced NSCLC Who Progressed After Standard Regimens and the Preliminary Analysis of an Efficacy Predictor.
    Cheng JD; Chai LX; Zhao ZP; Hao YY; Li S
    Cancer Manag Res; 2020; 12():5641-5650. PubMed ID: 32765067
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Implication of
    Li X; Cheng Y; Zhu B; Geng M; Yan P; Hu M
    Technol Cancer Res Treat; 2022; 21():15330338221080993. PubMed ID: 35443836
    [No Abstract]   [Full Text] [Related]  

  • 13. Safety and efficacy of ICI plus anlotinib vs. anlotinib alone as third-line treatment in extensive-stage small cell lung cancer: a retrospective study.
    Chen Q; Li Y; Zhang W; Wang C; Yang S; Guo Q
    J Cancer Res Clin Oncol; 2022 Feb; 148(2):401-408. PubMed ID: 34797416
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The real-world efficacy and safety of anlotinib in advanced non-small cell lung cancer.
    Wang F; Jin F; Cheng B; Zhang Y; Zhou Q; Wang S
    J Cancer Res Clin Oncol; 2022 Jul; 148(7):1721-1735. PubMed ID: 34357411
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase II study of anlotinib combined with etoposide and platinum-based regimens in the first-line treatment of extensive-stage small cell lung cancer.
    Liu C; Liao J; Wu X; Zhao X; Sun S; Wang H; Hu Z; Zhang Y; Yu H; Wang J
    Thorac Cancer; 2022 May; 13(10):1463-1470. PubMed ID: 35388976
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of tumor cavitation in extensive-stage small-cell lung cancer patients treated with anlotinib.
    Chen D; Xu J; Zhao Y; Chu T; Zhong H; Han B; Zhong R
    J Cancer Res Clin Oncol; 2020 Feb; 146(2):401-406. PubMed ID: 31691871
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Efficacy and Safety of Anlotinib Plus Etoposide with Cisplatin/Carboplatin in the First-Line Treatment of Lung Cancer: A Phase II Clinical Study.
    Lv XM; Liu Y; Feng Y; Liang HL; Zhi WW
    J Cancer; 2024; 15(11):3539-3546. PubMed ID: 38817880
    [No Abstract]   [Full Text] [Related]  

  • 18. Anlotinib combined with PD-1 blockade for the treatment of lung cancer: a real-world retrospective study in China.
    Zhang X; Zeng L; Li Y; Xu Q; Yang H; Lizaso A; Mao X; Jin R; Zeng Y; Li Q; Wang J; Li Y; Zhang Y; Yang N
    Cancer Immunol Immunother; 2021 Sep; 70(9):2517-2528. PubMed ID: 33566148
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical study of antinib combined with radiotherapy in the treatment of third-line extensive small cell lung cancer].
    Zong YF; Tan Y; Baerxiaguli Z; Wang HF
    Zhonghua Zhong Liu Za Zhi; 2023 Oct; 45(10):892-897. PubMed ID: 37875425
    [No Abstract]   [Full Text] [Related]  

  • 20. Effectiveness of anlotinib in patients with small-cell lung cancer and pleural effusion: Subgroup analysis from a randomized, multicenter, phase II study.
    Liu Y; Cheng Y; Wang Q; Li K; Shi J; Wu L; Han B; Chen G; He J; Wang J; Qin H; Li X
    Thorac Cancer; 2021 Nov; 12(22):3039-3045. PubMed ID: 34596367
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.